News & Updates

Placing awake COVID-19 patients with acute hypoxaemic respiratory failure (AHRF) in a prone position is an efficacious intervention in terms of both reducing mortality and preventing intubation, according to an individual participant data meta-analysis.

Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.

Interim data from the phase II COCOON trial demonstrate the potential of the COCOON dermatologic management (DM) regimen to significantly reduce the incidence and severity of dermatologic adverse events (dAEs) tied to amivantamab plus lazertinib treatment in patients with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).

In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.